Services - 133247-2020

19/03/2020    S56

Spain-Barcelona: Research and experimental development services

2020/S 056-133247

Contract award notice

Results of the procurement procedure

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: Agència de Qualitat i Avaluació Sanitària de Catalunya
National registration number: Q0801969G
Postal address: C. Roc Boronat, 81-95
Town: Barcelona
NUTS code: ES511 Barcelona
Postal code: 08005
Country: Spain
Contact person: Pau Aguilar; Ferran Trullàs; Lluis Granero
E-mail: contractes.aquas@gencat.cat
Telephone: +34 935513943
Fax: +34 935517510

Internet address(es):

Main address: http://antisuperbugs.eu/

Address of the buyer profile: https://contractaciopublica.gencat.cat/ecofin_pscp/AppJava/perfil/AQuAS

I.2)Information about joint procurement
I.4)Type of the contracting authority
Regional or local agency/office
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Pre-commercial Procurement to Buy R&D Services to Early Detecting Micro‐organisms that may Determine the Incurrence of Hospital-acquired Infections and to Controlling the Diffusion of Infections

II.1.2)Main CPV code
73100000 Research and experimental development services
II.1.3)Type of contract
Services
II.1.4)Short description:

This contract notice invites interested operators to submit tenders to a procurement.

The procurement aims to trigger new solutions to be developed and tested to address the following challenges:

— reducing both the healthcare and governmental costs and the operational impact resulting from infections caused by MDROs;

— improving the appropriateness and effectiveness of antimicrobial medicine usage;

— reducing the community and social care impact of MDROs acquired at hospitals through technologies that will transform current surveillance and infections control systems into new comprehensive systems.

This PCP procurement is a joint procurement by different procurers across Europe that are all facing the same common challenge and are thus looking for similar solutions (so-called ‘buyers group’).

II.1.6)Information about lots
This contract is divided into lots: no
II.1.7)Total value of the procurement (excluding VAT)
Value excluding VAT: 2 848 450.41 EUR
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)
73100000 Research and experimental development services
73300000 Design and execution of research and development
33000000 Medical equipments, pharmaceuticals and personal care products
38000000 Laboratory, optical and precision equipments (excl. glasses)
72000000 IT services: consulting, software development, Internet and support
48180000 Medical software package
II.2.3)Place of performance
NUTS code: ES51 Cataluña
Main site or place of performance:

For each Phase at least 51 % of the R&D services need to be performed within the EU Member States, or a country that is associated to the Horizon 2020.

II.2.4)Description of the procurement:

This is a joint procurement involving different countries and the state applicable national procurement law is the Spanish one.

The lead procurer (Agència de Qualitat i Avaluació Sanitària de Catalunya) is appointed to coordinate and lead the joint PCP, and to sign and award the framework agreement and the specific contracts for all phases of the PCP, in the name and on behalf of the following Buyers Group:

• ICO/ VINCat (Catalan Institute of Oncology/Catalan Nosocomial Infections Surveillance). Spain

• UKA (Aachen University Hospital). Germany

• STH (Sheffield Teaching Hospitals NHS Foundation Trust. UK

• PAT (Provincia Autonoma di Trento). Italy

• HELIOS (HELIOS Universitätsklinikum Wuppertal). Germany

• FMT (Fundació Mutua de Terrassa). Spain.

The Lead Procurer is not part of the Buyers Group.

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to a number of R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions.

Each selected operator will be awarded a framework agreement that covers 3 R&D phases. The 3 phases are:

— R&D up to solution design

— R&D up to a prototype

— R&D up to original development, validation and testing of a limited set of first products or services.

Testing is expected to take place in the facilities of the members of the Buyers Group FMT, PAT and HELIOS.

This testing may also serve as a first customer test reference for the contractors. The procurement – from the tender procedure until the subsequent performance of contracts – is expected to start in 28 July 2019 and to end in 31 August 2021.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions beyond the procurers

II.2.5)Award criteria
Quality criterion - Name: Technical offer / Weighting: 90
Cost criterion - Name: Financial offer / Weighting: 10
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:

This procurement receives funding from the European Union’s Horizon 2020 Research and Innovation Programme (H2020-EU.2.1. — Industrial Leadership — leadership in enabling and industrial technologies- Information and Communication Technologies (ICT)) under Grant Agreement No 688878. The EU has given a grant for this procurement, but is not participating as a contracting authority in the procurement.

II.2.14)Additional information

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.6)Information about electronic auction
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: no
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
Notice number in the OJ S: 2019/S 142-349721
IV.2.8)Information about termination of dynamic purchasing system
IV.2.9)Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

Title:

Pre-commercial Procurement to Buy R&D Services to Early Detecting Micro‐organisms that may Determine the Incurrence of Hospital-acquired Infections and to Controlling the Diffusion of Infections

A contract/lot is awarded: yes
V.2)Award of contract
V.2.1)Date of conclusion of the contract:
12/03/2020
V.2.2)Information about tenders
Number of tenders received: 6
The contract has been awarded to a group of economic operators: yes
V.2.3)Name and address of the contractor
Official name: Tech4care SRL
Town: Falconara Marittima
NUTS code: IT ITALIA
Country: Italy
The contractor is an SME: yes
V.2.3)Name and address of the contractor
Official name: Culture (Bahia-Gradiant-INL)
Town: Ames
NUTS code: ES ESPAÑA
Country: Spain
The contractor is an SME: yes
V.2.3)Name and address of the contractor
Official name: Bugwatcher
Town: Sant Cugat
NUTS code: ES ESPAÑA
Country: Spain
The contractor is an SME: yes
V.2.3)Name and address of the contractor
Official name: ASB- IMS2
Town: Dortmund
NUTS code: DE DEUTSCHLAND
Country: Germany
The contractor is an SME: yes
V.2.4)Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: 2 848 450.41 EUR
Total value of the contract/lot: 2 848 450.41 EUR
V.2.5)Information about subcontracting

Section VI: Complementary information

VI.3)Additional information:

Participation in the open market consultation that was held as part of the preparation for this procurement is not a prerequisite for submitting a tender.

This procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authority for its use in the conduct of its own affairs.

Publication of this contract notice in the EU Official Journal is not to be understood as a waiver of this exemption. Publication is made on a voluntary basis and the procurement will not follow the procedures under the EU public procurement directives, but rather the procedure described in the tender documentation.

The open procedure was chosen in Section IV.1.1) ‘Procedure’ for formal reasons only. This is because it is not possible to publish a contract notice without selecting one of the listed procedures.

Offers may be submitted in English and either Catalan or Spanish (please read the Request for Tenders document). All communication (before, during and after the procurement) can be made in English, Spanish and Catalan (please read the request for tenders document)

See:

The project website http://antisuperbugs.eu/

The open market consultation Q&A http://antisuperbugs.eu/index.php/market-consultation-2/

PCPs on the Europa website (see https://ec.europa.eu/digital-single-market/innovation-procurement) or contact:

antisuperbugs.AQUAS@gencat.cat

VI.4)Procedures for review
VI.4.1)Review body
Official name: The Head of the Health Department of the Government of Catalonia (‘Consellera de Salut de la Generalitat de Catalunya’)
Town: Barcelona
Country: Spain
VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
Precise information on deadline(s) for review procedures:

The procurement is exempted from the EU public procurement directives (including the EU procurement remedies directives 89/665/EEC and 92/13/EEC — see above) and the national laws that implement them.

Publication of this notice in the Official Journal is not to be understood as a waiver of this exemption by the contracting authority.

Any legal claim, petition or application for judicial review, with regard to the Anti-Superbugs PCP Procedure, whether before civil or administrative courts, shall be made before the Spanish jurisdiction. By submitting a bid, the bidder accepts the exclusive jurisdiction of Spanish courts and waives any other jurisdiction which may correspond to them.

Decisions taken with regard to the selection of Bidders, awarding them with Phases 1, 2 or 3 or excluding them from the Anti-Superbugs PCP Procedure should be challenged by means of an administrative remedy (‘recurso de alzada’) before the Head of the Health Department of the Government of Catalonia (‘Consellera de Salut de la Generalitat de Catalunya’) within a period of maximum one month upon the formal notification of the decision. The decision of the Head of the Health Department dismissing the ‘recurso de alzada’ could be challenged before the Administrative Courts (‘Sala de lo Contencioso Administrativo del Tribunal Superior de Justicia de Cataluña’) within a period of 2 months upon the formal notification of the decision.

Any dispute or claim arising out of or in connection with the execution of the FA or of the phases contracts entered into between the lead procurer and the contractor, shall be heard by the Civil Courts (‘Juzgados de Primera Instancia de Barcelona’).

VI.4.4)Service from which information about the review procedure may be obtained
VI.5)Date of dispatch of this notice:
17/03/2020